shutterstock_173790767_360b
360b / Shutterstock.com
28 February 2019Big Pharma

Judge orders Boehringer to disclose Humira biosimilar plans

A US judge has ordered Boehringer Ingelheim to release its rollout plans for a biosimilar version of Humira (adalimumab), following a request from AbbVie.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
3 August 2017   Boehringer Ingelheim has infringed 74 of AbbVie’s patents relating to arthritis medication Humira (adalimumab), AbbVie has alleged.

More on this story

Americas
3 August 2017   Boehringer Ingelheim has infringed 74 of AbbVie’s patents relating to arthritis medication Humira (adalimumab), AbbVie has alleged.

More on this story

Americas
3 August 2017   Boehringer Ingelheim has infringed 74 of AbbVie’s patents relating to arthritis medication Humira (adalimumab), AbbVie has alleged.